The clinical relevance of VPA as an anticancer therapeutic agent is well established, supporting HDAC inhibition for APP enhancement, either as a single agent or by augmenting standard of care in patients with tumors expressing high DcR3 levels, such as pancreatic cancer [56, 58]. Here, HDAC9 is linked to pancreatic neoplasm.